Figure 3

Proof of principle of the assay system. (A) Flow cytometric assessment of CB1954-resistant clone expressing RFP-TMnfsB. HT2, LT1, and LT3 were treated with 1 μM decitabine and/or 1, 2 μM of vorinostat (SAHA) for 48 hours. The average red-fluorescence of the treated cells (n = 3) were correlated with the mRNA expression of (B) TMnfsB of treated HT2 and LT3 (C) TXNIP and (D) ANKRD11 of treated LT1 cells normalized to β-actin expression (n = 1). The red-fluorescent reading for TXNIP and ANKRD11 analysis was normalized to vehicle control. All treatments contain <1% v/v of DMSO.